Added to YB: 2025-02-14
Pitch date: 2025-02-12
AVIR [bullish]
Atea Pharmaceuticals, Inc.
+0.64%
current return
Author Info
Turtles Research writes short articles about mis-priced boring stocks around the world. Sign up for the newsletter.
Company Info
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Market Cap
$266.1M
Pitch Price
$3.13
Price Target
5.30 (+68%)
Dividend
N/A
EV/EBITDA
1.73
P/E
-1.52
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Reviving two old ideas - Atea Pharmaceuticals, Inc.
AVIR: $5.3/sh net cash, $1.2/sh annual burn. 3 activists own 20%. Strategic alternatives announced. HCV drug in Phase III. 4 scenarios: 1) Cash burn continues 2) HCV partner found 3) Liquidation (50-70% upside) 4) Reverse merger. Headcount reduction expected. Previous $5.75 bid rejected.
Read full article (2 min)